Literature DB >> 31712804

Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States.

Jessica Williams-Nguyen, Stephen E Hawes, Robin M Nance, Sara Lindström, Susan R Heckbert, H Nina Kim, W Chris Mathews, Edward R Cachay, Matt Budoff, Christopher B Hurt, Peter W Hunt, Elvin Geng, Richard D Moore, Michael J Mugavero, Inga Peter, Mari M Kitahata, Michael S Saag, Heidi M Crane, Joseph A Delaney.   

Abstract

Hepatitis C virus (HCV) infection is common among people living with human immunodeficiency virus (PLWH). Extrahepatic manifestations of HCV, including myocardial infarction (MI), are a topic of active research. MI is classified into types, predominantly atheroembolic type 1 MI (T1MI) and supply-demand mismatch type 2 MI (T2MI). We examined the association between HCV and MI among patients in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems, a US multicenter clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Third Universal Definition of Myocardial Infarction. We estimated the association between chronic HCV (RNA+) and time to MI while adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics, and history of injecting drug use. Among 23,407 PLWH aged ≥18 years, there were 336 T1MIs and 330 T2MIs during a median of 4.7 years of follow-up between 1998 and 2016. HCV was associated with a 46% greater risk of T2MI (adjusted hazard ratio (aHR) = 1.46, 95% confidence interval (CI): 1.09, 1.97) but not T1MI (aHR = 0.87, 95% CI: 0.58, 1.29). In an exploratory cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR = 2.01, 95% CI: 1.25, 3.24). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; HIV coinfection; chronic hepatitis C infection; hepatitis C virus; myocardial infarction; people living with HIV; type 2 myocardial infarction

Mesh:

Year:  2020        PMID: 31712804      PMCID: PMC7443203          DOI: 10.1093/aje/kwz236

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  52 in total

1.  Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment.

Authors:  Cian P McCarthy; Muthiah Vaduganathan; James L Januzzi
Journal:  JAMA       Date:  2018-08-07       Impact factor: 56.272

2.  HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis.

Authors:  O Osibogun; O Ogunmoroti; E D Michos; E S Spatz; B Olubajo; K Nasir; P Madhivanan; W Maziak
Journal:  J Viral Hepat       Date:  2017-06-23       Impact factor: 3.728

3.  Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.

Authors:  Mei-Hsuan Lee; Hwai-I Yang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Li-Yu Wang; Chih-Hao Wang; Wei J Chen; Chien-Jen Chen
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

4.  Discordance between ICD-Coded Myocardial Infarction and Diagnosis according to the Universal Definition of Myocardial Infarction.

Authors:  Jorge Díaz-Garzón; Yader Sandoval; Stephen W Smith; Sara Love; Karen Schulz; Sarah E Thordsen; Benjamin K Johnson; Brian Driver; Katherine Jacoby; Michelle D Carlson; Kenneth W Dodd; Johanna Moore; Nathaniel L Scott; Charles A Bruen; Ryan Hatch; Fred S Apple
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

5.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

6.  Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  Ellen M Tedaldi; Katherine Huppler Hullsiek; Carlos D Malvestutto; Roberto C Arduino; Evelyn J Fisher; Paul J Gaglio; Elizabeth R Jenny-Avital; Joseph P McGowan; George Perez
Journal:  Clin Infect Dis       Date:  2003-05-06       Impact factor: 9.079

7.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

Review 8.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Authors:  Lucy Platt; Philippa Easterbrook; Erin Gower; Bethan McDonald; Keith Sabin; Catherine McGowan; Irini Yanny; Homie Razavi; Peter Vickerman
Journal:  Lancet Infect Dis       Date:  2016-02-25       Impact factor: 25.071

9.  Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.

Authors: 
Journal:  Lancet HIV       Date:  2017-05-10       Impact factor: 12.767

Review 10.  Era of direct acting anti-viral agents for the treatment of hepatitis C.

Authors:  Monjur Ahmed
Journal:  World J Hepatol       Date:  2018-10-27
View more
  1 in total

1.  Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease.

Authors:  Diego Casas-Deza; Ana Martínez-Sapiña; Silvia Espina; Beatriz Garcia-Rodriguez; Eva M Fernandez-Bonilla; Alejandro Sanz-Paris; Yolanda Gonzalez-Irazabal; Vanesa Bernal-Monterde; Jose M Arbones-Mainar
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.